Related Experiment Videos
Morphologic and molecular prognostic markers in prostate cancer
Jeffrey S Ross1, Christine E Sheehan, Eric M Dolen
1Department of Pathology, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu
Advances in Anatomic Pathology
|March 28, 2002
Summary
This review compares traditional, ancillary, and molecular methods for predicting prostate cancer prognosis. It assesses their clinical utility and validation status for guiding treatment decisions.
Area of Science:
- Oncology
- Pathology
- Biomarkers
Background:
- Prostate cancer prognosis relies on accurate predictive factors.
- Traditional methods include morphology and ancillary biomarkers.
- Emerging molecular assays offer new predictive potential.
Purpose of the Study:
- To evaluate the prognostic capabilities of various prostate cancer assessment methods.
- To compare established (Category I), emerging (Category II), and unvalidated (Category III) prognostic factors.
- To inform clinical practice and future research in prostate cancer prognostication.
Main Methods:
- Review of traditional morphology-based measurements.
- Evaluation of well-documented ancillary biomarkers.
- Assessment of emerging molecular assays for prostate cancer prognosis.
Main Results:
- Comparison of Category I (widespread use) prognostic factors.
- Analysis of Category II (clinical practice) tests.
- Review of Category III (emerging, unvalidated) molecular assays.
Conclusions:
- Established prognostic factors provide a baseline for comparison.
- Emerging tests require further validation for clinical integration.
- Molecular assays represent a future direction for personalized prostate cancer management.